Biotech | April 08, 2022
CDSCO approves Phase II/III trial of Akston Bio’s Covid vaccine candidate in India
Veeda Clinical Research will submit data in an application for Emergency Use Authorisation
Veeda Clinical Research will submit data in an application for Emergency Use Authorisation
If authorized by the USFDA, the Proof Lab Test System may be used to deliver accurate, actionable, lab-quality results for Covid-19 in as little as 18 minutes
Makrolon polycarbonate is key to needle-free injections that can stand up to sterilization
Pilots to be launched across multiple locations in India.
If approved, it will be the first USFDA-approved immunomodulator for the treatment of Covid-19 in hospitalised patients
Primarily set up to address the Covid-19 emergency, the WHO technology transfer hub has the potential to expand manufacturing capacity for other products as well, including treatments, and target other priorities such as malaria, HIV and cancer
WHO’s post EUA inspection found deficiencies in Good Manufacturing Practice at the facility
The fund has already invested in seven companies including Medikabazaar, THB, Impact Guru, Stanplus, Ekincare, Qure.ai and HealthifyMe
50 µg dose approved for all adults over 50 years of age and immunocompromised adults over 18 years of age
Evusheld significantly reduced the risk of developing symptomatic COVID-19 in PROVENT Phase III trial, with protection lasting at least six months
Subscribe To Our Newsletter & Stay Updated
